Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 4,757	$ 17,525
Prepaid expenses and other current assets	6,955	1,548
Total Current Assets	11,712	19,073
Property and equipment, net	107	65
Deposits and other assets	18	6
Total Assets	11,837	19,144
Current Liabilities:
Accounts payable	8,686	996
Accrued expenses	1,615	1,298
Warrant liabilities	14,803	6,756
Accrued employee benefits	394	538
Total Current Liabilities	25,498	9,588
Total Liabilities	$ 25,498	$ 9,588
Commitments and Contingencies
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	$ 0	$ 0
Common stock, $0.001 par value; 250,000,000 shares authorized, 73,260,787 issued and 73,179,305 outstanding and 72,594,626 issued and 72,513,144 outstanding	73	72
Additional paid-in capital	113,289	110,526
Accumulated deficit	(127,023)	(101,042)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)	(13,661)	9,556
Non-controlling interest	0	0
Total Stockholders' Equity (Deficit)	(13,661)	9,556
Total Liabilities and Stockholders' Equity (Deficit)	$ 11,837	$ 19,144